

March 26, 2021

**Via EDGAR Transmission**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Mail Stop 4720  
Washington, D.C. 20549

Attention: David Gessert

**Re: Verona Pharma plc  
Registration Statement on Form S-3  
Filed March 19, 2021  
Registration No. 333-254530**

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on March 29, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Verona Pharma plc (the "Company") or its counsel may request via telephone call to the staff. Please contact Peter Handrinos of Latham & Watkins LLP, counsel to the Company, at (617) 948-6060, or in his absence, Jennifer Yoon at (617) 880-4540, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

---

Sincerely yours,

**Verona Pharma plc**

By: /s/ Claire Poll  
Claire Poll  
General Counsel

---

cc: Peter N. Handrinos, Esq.

---